摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-pentylquinoline-3-carbaldehyde | 1399086-07-7

中文名称
——
中文别名
——
英文名称
2-pentylquinoline-3-carbaldehyde
英文别名
2-Pentylquinoline-3-carbaldehyde
2-pentylquinoline-3-carbaldehyde化学式
CAS
1399086-07-7
化学式
C15H17NO
mdl
——
分子量
227.306
InChiKey
UKBIJPYSHJFQEW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    17
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    30
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为产物:
    描述:
    silica gel三乙胺 作用下, 以 氯仿 为溶剂, 反应 27.0h, 生成 2-pentylquinoline-3-carbaldehyde
    参考文献:
    名称:
    多取代喹啉和手性1,4-二氢喹啉的有机催化级联方法-N保护基团的出乎意料的影响
    摘要:
    保护问题:有机合成的有机催化氮杂Michael / aldol级联反应向喹啉和1,4-二氢喹啉的反应取决于N保护基的选择(参见方案; TEA =三乙胺,TMS =三甲基甲硅烷基)。给电子的磺酰基的使用会导致意料之外的氮杂-迈克尔/羟醛/芳香化反应级联反应,生成多取代的喹啉(右图)。相反,手性的1,4-二氢喹啉具有吸电子磺酰基(左)。
    DOI:
    10.1002/anie.201202161
点击查看最新优质反应信息

文献信息

  • Heterocyclic compounds and their uses
    申请人:Chen Yi
    公开号:US20090030002A1
    公开(公告)日:2009-01-29
    Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelodysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.
    含有替代双环杂环芳基的化合物及其组合物,用于治疗一般性炎症、关节炎、风湿性疾病、骨关节炎、炎性肠病、炎性眼部疾病、炎性或不稳定膀胱疾病、牛皮癣、具有炎症成分的皮肤问题、慢性炎症状况,包括但不限于自身免疫疾病,如系统性红斑狼疮(SLE)、重症肌无力、类风湿性关节炎、急性播散性脑脊髓炎、特发性血小板减少性紫癜、多发性硬化症、Sjogren综合症和自身免疫性溶血性贫血,包括所有过敏形式的过敏症。本发明还提供了治疗与p110δ活性有关、依赖于或与之相关的癌症的方法,包括但不限于白血病,如急性髓细胞白血病(AML)、骨髓增生异常综合症(MDS)、骨髓增生性疾病(MPD)、慢性髓细胞白血病(CML)、T细胞急性淋巴细胞白血病(T-ALL)、B细胞急性淋巴细胞白血病(B-ALL)、非霍奇金淋巴瘤(NHL)、B细胞淋巴瘤和固体肿瘤,如乳腺癌。
  • HETEROCYCLIC COMPOUNDS AND THEIR USES
    申请人:Chen Yi
    公开号:US20110152277A1
    公开(公告)日:2011-06-23
    Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.
    含有替代双环杂环芳基的化合物和组合物,用于治疗一般炎症、关节炎、风湿性疾病、骨关节炎、炎症性肠病、炎症性眼疾、炎症性或不稳定的膀胱疾病、牛皮癣、具有炎症成分的皮肤病、慢性炎症病症,包括但不限于自身免疫性疾病,如系统性红斑狼疮(SLE)、重症肌无力、类风湿性关节炎、急性播散性脑脊髓炎、特发性血小板减少性紫癜、多发性硬化症、Sjoegren综合征和自身免疫性溶血性贫血;过敏症,包括所有类型的超敏反应。本发明还提供了用于治疗与p110δ活性有关、依赖或相关的癌症的方法,包括但不限于白血病,如急性髓系白血病(AML)、骨髓增生异常综合征(MDS)、骨髓增生性疾病(MPD)、慢性髓性白血病(CML)、T细胞急性淋巴细胞白血病(T-ALL)、B细胞急性淋巴细胞白血病(B-ALL)、非霍奇金淋巴瘤(NHL)、B细胞淋巴瘤和实体肿瘤,如乳腺癌。
  • 3- SUBSTITUTED QUINOLINE OR QUINOXALINE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE ( PI3K) INHIBITORS
    申请人:Amgen Inc.
    公开号:EP2139882A1
    公开(公告)日:2010-01-06
  • 3- SUBSTITUTED QUINOLINE OR QUINOXALINE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS
    申请人:Amgen Inc.
    公开号:EP2139882B1
    公开(公告)日:2013-12-25
  • US7705018B2
    申请人:——
    公开号:US7705018B2
    公开(公告)日:2010-04-27
查看更多